BioNTech PT receives Investment Bank Analyst Rating Update
By Geoffrey Smith Investing.com -- Two key lieutenants of Sam Bankman-Fried entered guilty pleas and said they will cooperate with the investigation against their former...
By Sam Boughedda BofA analysts upgraded BioNTech SE (NASDAQ:BNTX) to Buy from Neutral, maintaining a $239 price target on the stock in a note to clients Thursday. The upgrade is...
EU attempting to revive Iran nuclear deal with market staying pessimistic Crude prices could rebound from oversold conditions but stay off 2022 highs Both Iran, US likely looking...
Shares of Pfizer are down over 12.5% since the start of 2022. Plan to spend cash generated from COVID-19 vaccine on M&As and share buybacks. Long-term investors may consider...
Pharmaceuticals giant Pfizer (NYSE:PFE), co-developer with BioNTech (NASDAQ:BNTX) of one of the most widely used COVID-19 vaccines in the developed world, is scheduled to release...
BioNTech SE is a Germany-based clinical-stage biotechnology company. The Company focuses on patient-specific immunotherapies for the treatment of cancer and other serious diseases. The Company is providing technologies including mRNA-based therapies, cell therapies, small molecules and antibodies, which can be utilized for specific purposes or can be even combined with each other in a synergistic manner. It also develops a broad product pipeline using different scientific approaches and technology platforms, including individualized mRNA-based product candidates, chimeric antigen receptor T-cells, checkpoint immunomodulators, targeted cancer antibodies and small molecules. In addition, the Company offers diagnostic products and drug discovery services for other therapeutic areas, including infectious diseases, allergies and autoimmune disorders.
|Average||204.63 (+41.71% Upside)|
|No. of Analysts||15|